NUWIQ PUP Study

The largest prospective clinical trial of a single FVIII product in previously untreated patients with hemophilia A.

Review the NuProtect Study and Findings

News & stories

Check out our latest stories

As Omicron Spreads Nationally, Octapharma’s fibryga® & Octaplas™ Become Increasingly Important Replacement Therapies

Medical Providers Should Consider Replacing Cryoprecipitate and Fresh Frozen Plasma with Octaplas™ and fibryga® if Supplies Become Depleted

FDA Approves Octapharma’s cutaquig® 16.5% for Pediatric PI Patients, Providing Flexible Treatment Options

Families, Providers Can Utilize Flexible Infusion Schedule to Meet Patient Needs

FDA Orphan Drug Approval: Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis

Octagam® 10% Expected to Become the First Treatment Option for Adults with Rare Immune-mediated Inflammatory Disease

FDA Approves Octapharma's Octagam®10% for Adult Dermatomyositis

FDA Approval Based on Positive Results of International, Multi-center ProDERM Study

Patient engagement

Octapharma takes an active role in our community

We sponsor and support organizations worldwide.

Learn how we engage with patients

Our products

Products

Learn more about our products to treat rare diseases and other coagulopathies and bleeding disorders.